HELP

Cybin D/B/A Helus Pharma

Price Chart

Latest Quote

$6.51

-0.17 (-2.54%)

Current Price

Previous Close	$6.68
Open	$6.77
Day High	$6.78
Day Low	$6.40
Volume	476,272

Fetched: 2026-07-16T11:27:39

Stock Information

Note: Financial values converted from CAD to USD

Shares Outstanding	61.98M
Cash Equivalents	$147K
Net Income	$-105.56M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$449.38M
EPS (TTM)	$-4.38
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$952.80M
Income	$-105.56M
Book/sh	$0.05
Cash/sh	$0.00
Employees	100

Financial Ratios

Quick Ratio	8.38
Current Ratio	9.52

Returns & Margins

ROA	-41.35%
ROE	-74.60%

Ownership

Insider Ownership	2.75%
Institutional Ownership	39.86%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-3.08
P/B	138.64

Analyst Data

Recommendation	strong_buy
Target Price	$37.82

Technical Indicators

SMA20	$6.19
SMA50	$5.21
SMA200	$6.00
RSI	61.10
ATR	0.5046

Shares Float	99.77M
Short Ratio	2.42
Volatility	0.62
Rel Volume	1.69

Performance History

Week	+5.53%
Month	+69.00%
Quarter	+31.82%
6 Months	-10.93%
YTD	-12.44%
Year	-3.59%
3 Years	-60.25%
5 Years	-92.72%
10 Years	-85.50%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-07-17	$7.25	3,104,900
2026-07-16	$7.04	3,781,000
2026-07-15	$6.51	766,200
2026-07-14	$6.68	709,200
2026-07-13	$6.70	2,072,800
2026-07-10	$6.87	1,525,100
2026-07-09	$6.63	1,902,700
2026-07-08	$6.23	1,068,000
2026-07-07	$6.03	868,400
2026-07-06	$5.89	770,000
2026-07-02	$6.24	909,800
2026-07-01	$6.28	1,095,900
2026-06-30	$6.61	1,433,800
2026-06-29	$6.88	1,758,100
2026-06-26	$6.48	2,915,100
2026-06-25	$6.02	7,125,700
2026-06-24	$5.09	3,211,400
2026-06-23	$4.85	466,800
2026-06-22	$4.85	746,300
2026-06-18	$4.67	456,000

About Cybin D/B/A Helus Pharma

Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company' preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.

📰 Latest News

Cybin (HELP) Is Up 6.2% After Advancing HLP003 To Phase 3 And Raising US$50 Million

Simply Wall St. • 2026-07-17T09:13:09Z

Johnson & Johnson’s Spravato sales growth supports psychedelic drug opportunity: Jefferies

Proactive • 2026-07-15T19:34:00Z

Is Cybin D/B/A Helus Pharma (HELP) Stock a Psychedelic Medicine Opportunity Ahead of HLP003 Trial Results?

Insider Monkey • 2026-07-15T09:22:13Z

Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says

Proactive • 2026-07-13T18:59:00Z

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Market Exclusive • 2026-07-06T19:53:33Z

Cybin (HELP) Is Up 28.9% After Phase 3 HLP003 Progress And $50M Equity Raise - Has The Bull Case Changed?

Simply Wall St. • 2026-06-26T22:09:29Z

Does Robert Langer’s Arrival Reframe Confidence in Cybin’s (HELP) Clinical Strategy and Execution Risk?

Simply Wall St. • 2026-04-25T12:05:33Z

FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers Gain

MT Newswires • 2026-04-24T14:19:44Z

Trump Signed a Psychedelic Drugs Order—and These 4 Stocks Surged

Barrons.com • 2026-04-20T20:34:00Z

Psychedelic Shares Rise Following Trump's Executive Order to Accelerate Treatments for Serious Mental Illness

MT Newswires • 2026-04-20T11:23:51Z

Period:

Income Statement (Annual)

Metric	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Reconciled Cost Of Revenue	-	-	-	-
Cost Of Revenue	-	-	-	-
Expenses
Total Expenses	$101,591,705	$73,475,454	$56,169,803	$36,706,021
Other Income Expense	$-5,410,643	$11,077,783	$97,611	$2,440,276
Other Non Operating Income Expenses	$-1,842,497	-	-	-
Net Non Operating Interest Income Expense	$1,555,364	$4,267,811	$441,031	$429,631
Total Other Finance Cost	$2,078,331	-	-	-
Operating Expense	$101,591,705	$73,475,454	$56,169,803	$36,706,021
Selling And Marketing Expense	$4,594,131	$1,676,487	$1,998,998	$627,703
General And Administrative Expense	$35,304,555	$43,861,551	$22,506,793	$17,916,255
Interest Expense	-	-	-	-
Interest Expense Non Operating	-	-	-	-
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-105,446,984	$-58,144,110	$-55,631,161	$-33,836,114
Net Interest Income	$1,555,364	$4,267,811	$441,031	$429,631
Interest Income	$3,633,695	$4,267,811	$441,031	$429,631
Normalized Income	$-101,878,838	$-69,221,893	$-55,728,772	$-36,276,390
Net Income From Continuing And Discontinued Operation	$-105,446,984	$-58,144,110	$-55,631,161	$-33,836,114
Net Income Common Stockholders	$-105,446,984	$-58,144,110	$-55,631,161	$-33,836,114
Net Income	$-105,446,984	$-58,144,110	$-55,631,161	$-33,836,114
Net Income Including Noncontrolling Interests	$-105,446,984	$-58,129,860	$-55,631,161	$-33,836,114
Net Income Continuous Operations	$-105,446,984	$-58,129,860	$-55,631,161	$-33,836,114
Pretax Income	$-105,446,984	$-58,129,860	$-55,631,161	$-33,836,114
Interest Income Non Operating	$3,633,695	$4,267,811	$441,031	$429,631
Operating Income	$-101,591,705	$-73,475,454	$-56,169,803	$-36,706,021
Special Income Charges	-	$-19,950	$0	$-243,671
Gross Profit	-	-	-	-
Per Share
Diluted EPS	-	$-2.88	$-4.96	$-7.04
Basic EPS	-	$-2.88	$-4.96	$-7.04
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-97,938,060	$-84,305,291	$-55,965,318	$-38,967,462
Total Unusual Items	$-3,568,146	$11,077,783	$97,611	$2,440,276
Total Unusual Items Excluding Goodwill	$-3,568,146	$11,077,783	$97,611	$2,440,276
Reconciled Depreciation	$85,499	$247,946	$302,095	$178,835
EBITDA (Bullshit earnings)	$-101,506,206	$-73,227,508	$-55,867,707	$-36,527,186
EBIT	$-101,591,705	$-73,475,454	$-56,169,803	$-36,706,021
Diluted NI Availto Com Stockholders	$-105,446,984	$-58,144,110	$-55,631,161	$-33,836,114
Gain On Sale Of Security	$-3,568,146	$11,077,783	$97,611	$2,683,947
Research And Development	$61,693,019	$27,937,416	$23,057,577	$18,162,063
Selling General And Administration	$39,898,686	$45,538,038	$33,112,225	$18,543,958
Other Gand A	$20,464,829	$14,860,388	$10,835,510	$10,108,797
Salaries And Wages	$14,839,726	$29,001,162	$15,770,237	$7,807,457
Diluted Average Shares	-	$14,408,309	$5,911,787	$3,476,737
Basic Average Shares	-	$14,408,309	$5,911,787	$3,476,737
Other Special Charges	-	$19,950	-	-
Restructuring And Mergern Acquisition	-	-	$0	$243,671
Write Off	-	-	-	-
Impairment Of Capital Assets	-	-	-	-

Fetched: 2026-07-16

Balance Sheet (Annual)

Metric	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Assets
Net Tangible Assets	$117,802,973	$71,712,043	$148,900,991	$12,804,857
Total Assets	$178,953,075	$128,174,679	$215,188,141	$38,401,033
Total Non Current Assets	$47,483,134	$45,916,370	$59,483,590	$21,881,970
Goodwill And Other Intangible Assets	$47,344,198	$45,846,546	$59,093,858	$21,561,350
Other Intangible Assets	$21,534,275	$20,328,743	$25,268,431	$3,897,316
Current Assets	$131,469,941	$82,258,309	$155,704,551	$16,519,063
Prepaid Assets	$15,842,911	$10,980,884	$2,059,806	$1,234,744
Receivables	$3,582,396	$2,916,931	$3,189,102	$2,173,092
Accounts Receivable	$3,582,396	$2,916,931	$3,189,102	$2,173,092
Cash Cash Equivalents And Short Term Investments	$112,044,634	$66,918,415	$148,904,553	$11,850,834
Cash And Cash Equivalents	$112,044,634	$66,918,415	$148,904,553	$11,850,834
Cash Financial	$112,044,634	$66,918,415	$148,904,553	$11,850,834
Other Current Assets	-	$1,442,078	$1,551,089	$1,260,393
Debt
Total Debt	-	$0	$207,334	-
Current Debt And Capital Lease Obligation	-	-	$207,334	-
Liabilities
Total Liabilities Net Minority Interest	$13,805,904	$10,616,090	$7,193,291	$4,034,827
Total Non Current Liabilities Net Minority Interest	$0	$0	$0	$0
Current Liabilities	$13,805,904	$10,616,090	$7,193,291	$4,034,827
Payables And Accrued Expenses	$13,805,904	$10,616,090	$5,170,187	$4,034,827
Payables	-	$15,260,095	$5,170,187	$4,034,827
Accounts Payable	-	$15,260,095	$6,985,957	$4,034,827
Other Payable	-	-	$207,334	-
Tradeand Other Payables Non Current	-	-	-	-
Other Non Current Liabilities	-	-	-	-
Other Current Liabilities	-	-	-	-
Equity
Common Stock Equity	$165,147,171	$117,558,589	$207,994,849	$34,366,206
Total Equity Gross Minority Interest	$165,147,171	$117,558,589	$207,994,849	$34,366,206
Stockholders Equity	$165,147,171	$117,558,589	$207,994,849	$34,366,206
Other Equity Interest	$61,393,061	$40,437,327	$46,180,703	$27,185,740
Gains Losses Not Affecting Retained Earnings	$5,759,051	$-10,185,746	$-1,628,038	$-1,449,916
Other Equity Adjustments	$5,759,051	$-10,185,746	$-1,628,038	$-1,449,916
Retained Earnings	$-277,539,500	$-181,964,767	$-161,187,156	$-105,555,995
Other
Ordinary Shares Number	$36,787,105	$15,397,394	$14,251,461	$3,672,306
Share Issued	$36,787,105	$15,397,394	$14,251,461	$3,672,306
Tangible Book Value	$117,802,973	$71,712,043	$148,900,991	$12,804,857
Invested Capital	$165,147,171	$117,558,589	$207,994,849	$34,366,206
Working Capital	$117,664,037	$71,642,219	$148,511,259	$12,484,237
Total Capitalization	$165,147,171	$117,558,589	$207,994,849	$34,366,206
Additional Paid In Capital	$24,917,174	$23,245,674	$8,371,749	$1,497,652
Capital Stock	$350,617,385	$246,026,100	$316,257,591	$112,688,725
Common Stock	$350,617,385	$246,026,100	$316,257,591	$112,688,725
Goodwill	$25,809,923	$25,517,802	$33,825,427	$17,664,033
Net PPE	$138,935	$69,824	$389,732	$320,620
Accumulated Depreciation	$-438,893	$-419,656	$-574,979	$-322,758
Gross PPE	$577,829	$489,480	$964,710	$643,378
Other Properties	$294,258	$339,857	$775,188	$473,093
Machinery Furniture Equipment	$283,571	$149,623	$189,522	$170,285
Capital Lease Obligations	-	$0	$207,334	-
Current Capital Lease Obligation	-	$0	$207,334	-
Treasury Shares Number	-	-	$0	-
Investments And Advances	-	-	-	$0

Fetched: 2026-07-16

Cash Flow Statement (Annual)

Metric	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Free Cash Flow
Free Cash Flow	$-95,932,403	$-52,527,557	$-49,602,077	$-36,151,705
Operating Activities
Operating Cash Flow	$-94,954,155	$-51,532,922	$-49,096,209	$-33,794,078
Cash Flow From Continuing Operating Activities	$-94,954,155	$-51,532,922	$-49,096,209	$-33,794,078
Operating Gains Losses	$-355,532	$-11,077,783	$-97,611	$-2,867,769
Investing Activities
Capital Expenditure	$-978,248	$-994,635	$-505,867	$-2,357,627
Investing Cash Flow	$-971,123	$-994,635	$4,931,851	$-2,357,627
Cash Flow From Continuing Investing Activities	$-971,123	$-994,635	$4,931,851	$-2,357,627
Financing Activities
Issuance Of Capital Stock	$104,060,480	$10,192,159	$181,399,763	$9,406,283
Financing Cash Flow	$141,243,156	$10,042,536	$181,333,502	$9,664,204
Cash Flow From Continuing Financing Activities	$141,243,156	$10,042,536	$181,333,502	$9,664,204
Net Other Financing Charges	$-224,434	-	-	-
Net Common Stock Issuance	$104,060,480	$10,192,159	$181,399,763	$9,406,283
Common Stock Issuance	$104,060,480	$10,192,159	$181,399,763	$9,406,283
Other
Repayment Of Debt	$-14,356,658	$-149,623	$-106,161	$0
Issuance Of Debt	$31,705,772	$0	-	-
End Cash Position	$112,044,634	$66,918,415	$148,904,553	$11,850,834
Beginning Cash Position	$66,918,415	$109,892,917	$11,850,834	$38,218,636
Effect Of Exchange Rate Changes	$-191,660	$-489,480	$-115,423	$119,698
Changes In Cash	$45,317,879	$-42,485,021	$137,169,143	$-26,487,500
Proceeds From Stock Option Exercised	$20,057,997	$0	$39,899	$257,921
Net Issuance Payments Of Debt	$17,349,113	$-149,623	$-106,161	$0
Net Short Term Debt Issuance	$17,349,113	$0	-	-
Short Term Debt Payments	$-14,356,658	$0	-	-
Short Term Debt Issuance	$31,705,772	$0	-	-
Net Long Term Debt Issuance	$0	$-149,623	$-106,161	$0
Long Term Debt Payments	$0	$-149,623	$-106,161	$0
Net PPE Purchase And Sale	$-971,123	$-994,635	$-374,384	$-101,173
Sale Of PPE	$7,125	$0	-	-
Purchase Of PPE	$-978,248	$-994,635	$-374,384	$-101,173
Change In Working Capital	$-895,599	$-4,861,314	$-3,581,683	$-1,023,847
Change In Other Current Assets	$1,442,078	$-297,108	$-290,696	$-304,945
Change In Payables And Accrued Expense	$3,189,814	$5,459,093	$-1,812,573	$285,708
Change In Prepaid Assets	$-4,862,027	$-9,460,432	$-702,514	$-329,170
Change In Receivables	$-665,465	$-562,867	$-775,901	$-675,440
Changes In Account Receivables	$-665,465	$-562,867	$-775,901	$-675,440
Stock Based Compensation	$7,739,771	$22,288,089	$9,893,626	$3,338,725
Unrealized Gain Loss On Investment Securities	$3,918,691	$0	$0	$185,247
Depreciation Amortization Depletion	$85,499	$247,946	$302,095	$178,835
Depreciation And Amortization	$85,499	$247,946	$302,095	$178,835
Amortization Cash Flow	$22,800	$46,312	$43,462	$26,362
Amortization Of Intangibles	$22,800	$46,312	$43,462	$26,362
Depreciation	$62,699	$292,121	$258,634	$152,473
Net Foreign Currency Exchange Gain Loss	$-350,545	$-11,077,783	$-97,611	$-2,867,769
Gain Loss On Sale Of PPE	$-4,987	$0	-	-
Net Income From Continuing Operations	$-105,446,984	$-58,144,110	$-55,631,161	$-33,836,114
Net Business Purchase And Sale	-	$0	$5,437,718	$0
Sale Of Business	-	$0	$5,437,718	$0
Other Non Cash Items	-	$14,250	$5,700	$230,847
Asset Impairment Charge	-	$0	$12,825	$0
Net Intangibles Purchase And Sale	-	-	$-490,905	$-2,256,453
Purchase Of Intangibles	-	-	$-490,905	$-2,256,453
Net Investment Purchase And Sale	-	-	-	$0
Purchase Of Investment	-	-	-	$0
Purchase Of Business	-	-	-	-
Change In Inventory	-	-	-	-
Gain Loss On Investment Securities	-	-	-	-

Fetched: 2026-07-16